Target

renal cell carcinoma

3 abstracts

Abstract
Nivolumab as second-line treatment of patients with metastatic renal cell carcinoma with high or normal fibrinogen levels: A prospective, cohort study.
Org: Bureau for Cancer Research - BUCARE, City Clinical Cancer Hospital No. 1, Institute of Oncology Angel H Roffo, Hadassah Medical Moscow, State Budgetary Healthcare Institution Saint-Petersburg Clinical Scientific and Practical Center for Specialised Types of Medical Care,